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Burning Mouth Syndrome (BMS) is a disease that manifests as burning in the tongue or in any area of the oral 
mucosa, in the absence of clinically verifiable injuries. 
Objectives: To verify the efficacy of alpha lipoic acid (ALA) and gabapentin (GABA), used individually and 
jointly, to reduce the burning in patients with burning mouth and establish a drug therapy for the BMS. 
Study Design: During April and May 2008, we conducted a randomized, double-blind, placebo-controlled trial 
in the Department of Clinical Stomatology, Faculty of Dentistry, Rosario, Argentina. The gathering of patients 
was between those ones with BMS who were treated in our service between March 2003 and March 2008 without 
complying with the applied treatments. The 120 patients were randomly divided into 4 groups and were provided, 
by lot and in a blinded fashion, with four different treatment cycles consisting of the following drugs: Group A 
(n = 20) 600 mg / day of alpha lipoic acid for two months, Group B (n = 20) 300 mg / day of gabapentin for two 
months, Group C (n = 20) a combination of both drugs for two months and Group D (n = 60) 100 mg / day of ce-
llulose starch for two months (control group). 
Results and Conclusions: All 120 patients completed the treatment. The best response was obtained with the com-
bination of ALA + GABA, with a 70% of the cases with reduced burning in this group and a 13.2 times greater 
chance of presenting positive changes for these patients than those taking placebo. The combined use of drugs that 
act at different levels of the nociceptive system can be useful for the treatment of this syndrome.
Key words: Burning mouth syndrome, pharmacological treatment o� burning mouth, alpha lipoic acid, gabapen-
tin, oral neuropathic pain.
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Introduction
Burning mouth syndrome (BMS) is a disease charac-
terized by the presence of burning mouth, taste distur-
bances and dry mouth sensation in the absence of in-
juries that justify it (1-3). The sensation of “burning” 
generally involves the tongue, at its tip and edges, and 
can be extended to any area of the mouth. It often occurs 
more frequently in women over 60 years in the peri-or 
postmenopausal period; it is rarely found in men (1,2). 
The etiology is unknown but it’s believed to be multifac-
torial; patients with BMS often have anxiety and clini-
cal depression (4,5). Among the important local factors 
dental trauma, the presence of tartar, rough surfaces 
prosthesis, allergic reactions to dental materials, chemi-
cal irritants of lipsticks, toothpastes and prolonged use 
of mouthwashes may be included. Among the general 
factors deficiency states, deficiencies of iron, folic acid 
and vitamin B are important (6-9). Alpha Lipoic Acid is 
a component produced in the body in very small quanti-
ties, being present in many foods such as spinach, broc-
coli and meats. This substance acts as a coenzyme in 
various reactions, taking part in glycolysis - responsible 
for the conversion of blood sugar into energy- and in 
the regeneration of liver tissue damage. It also exerts 
a neuro-regenerative action, because it crosses the he-
matoencephalic barrier and has a protective effect of 
brain and nerve tissue (10,11). A systematic review of 
the Cochrane Collaboration, noted that Alpha-Lipoic 
Acid (ALA) may help in management of burning mouth 
syndrome (12). Various studies have shown that the use 
of ALA did not produce greater benefits on the burning 
mouth that the use of placebos (13,14). Gabapentin is an 
anticonvulsant whose chemical structure consists of a 
molecule of gamma-aminobutyric acid covalently linked 
to a lipophilic cyclohexane ring. This drug was created 
to act as an agonist of the inhibitory neurotransmitter 
GABA of central activity since it is easily transferred to 
the central nervous system (CNS) for having high lipid 
solubility. The mechanism of action of this drug is still 
unknown because it acts by increasing the discharge 
promoted of GABA but without noting a steady reduce 
in the potentials of action or affection of the calcium 
channel current (15). The objective of this research was 
to test the action of alpha lipoic acid and gabapentin 
alone and jointly, on the symptoms of BMS.
Patients and Methods
We conducted a randomized clinical double-blind, pla-
cebo-controlled clinical trial among patients with BMS 
seen at the Chair of Clinic Stomatology II of the Faculty 
of Dentistry, Rosario, Argentina. The study was ap-
proved by the Bioethics Committee of the Institution. 
Sample size was determined by considering a confidence 
level of 95% and an error rate of + / - 5%, determining the 
need to include a number of 120 patients for our study. 
The study was conducted during April and May 2008. 
The 120 patients were selected among those patients 
with BMS who have been treated at our service between 
March 2003 and March 2008, without responding to the 
applied treatments. A total of 120 patients with idiopathic 
BMS of more than three months duration that wanted to 
participate voluntarily were included. Polypharmacy pa-
tients using more than 3 systemically daily drugs, those 
ones taking psychotropic and antihypertensives drugs as 
well as patients with serious psychiatric conditions previ-
ously diagnosed were excluded. Patients with deficiencies 
of folic acid, vitamin B, carriers of anemias of any kind 
and patients with Sjögren syndrome were also excluded. 
Participants were warned of the possibility of access to 
different drugs as well as the possibility of being treated 
with placebo. An informed consent was signed where the 
scope of the study and the freedom to leave treatment at 
any time were specified, and also the provision of medi-
cation following the completion of the study was ensured. 
We performed an initial psychological diagnosis for all 
patients through the application of the Hospital Anxiety 
and Depression Scale (HAD) and the Hamilton Rating 
Scale for Depression in order to meet the psychological 
situation of our patients. Then we evaluated the presence 
of burning through a numerical scale especially created 
for this work, describing the burning from 0 to 4, where 
the 0 value corresponded to the absence of burning, the 
1 value to the presence of burning in a single area of the 
tongue, the 2 value to two distinctive areas (tongue and 
gums, tongue and lips or tongue and palate), the 3 value 
to three areas and the 4 value corresponded to burning 
spread throughout the mouth. This specific designed 
scale, which considered the geographical distribution of 
burning in different areas of the mouth, allowed us to dis-
tinguish improvements or deteriorations of burning sen-
sation in the various assessments. The 120 patients were 
randomly divided into 6 groups of 20 members each. 
Once the groups were formed, our service attendants as-
signed a numerical order for each group being identified 
as groups 1, 2, 3, 4, 5 and 6. On the other hand, six treat-
ment cycles were determined: cycles A, B, C, D, E and 
F, so that cycle A (n = 20) corresponded to 600 mg / day 
of ALA, the cycle B (n = 20) 300 mg / day of GABA, the 
cycle C (n = 20) to the combination of both drugs and the 
cycles D (n = 20), E (n = 20) and F (n = 20) were 100 mg 
/ day of starch and cellulose (Placebo). The support staff 
of our service made a draw with 6 balls to link the groups 
with the cycles of treatment. After the draw, the three 
groups were combined with cycles D, E and F to be treat-
ed with placebo, thus forming a single group for these 
patients, Group D (n = 60) or control group proceeding to 
medication delivery, allocation that was always masked 
to both patients and researcher, through the use of cap-
sules of similar size and appearance so that just the sup-
port staff was the one who recorded the information until 
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the end of the treatment (blind). The beginning of the ad-
ministration of the different drugs was concomitant for 
all patients, as well as the evaluation of the effects, which 
was made monthly and also blinded (double blind), al-
ways by the same researcher using the protocol described 
above, which was completed for the first time the day be-
fore the start of treatment and thirty and sixty days, re-
spectively. To evaluate the changes that occurred with the 
taking of the different drugs, it was established that the 
improvements (positive changes) involved the passage of 
a certain level or numerical category of burning to a low-
er one, the deteriorations (negative changes) involved an 
increase of a certain level of burning to a higher one and 
the total resolution indicated the total absence of burning, 
that is to say the transition from any higher value to zero 
value. In this way four categories were obtained for the 
analysis of the results: Category 1: with negative changes 
(deterioration), Category 2: no changes; Category 3: with 
positive changes (improvements) and Category 4: with 
total recovery. The Chi- square test was used for the anal-
ysis to an independent variable with a predictive value (P 
<0.05) and the Odds ratios were calculated to determine 
the relationship between treatment and its effect on the 
intensity of the burning with ( P <0.01). All subjects were 
evaluated through an Intention-to-Treat Analysis which 
would take into account all patients although they could 
discontinue the treatment.
Results
All patients included initially ended the study because 
the duration of treatment lasted only 2 months and the 
adverse effects that appeared were very mild. Of the 
120 patients studied, 94 were females and 26 males with 
a mean age of 14.1 ± 57.5 years, median: 57. The psy-
chological diagnosis showed 95 patients without pathol-
ogy (78%), 14 with anxiety (13%) and 11 with depres-
sion (9%). We assessed changes in levels of burning in 
each group after one and two months of treatment. The 
first month of treatment, changes in levels of burning 
were not dependent on the type of drug tested (p-value 
= 0.293) (Fig. 1). After 2 months of treatment, we found 
that the positive changes in the levels of burning, signif-
icantly depended on the type of drug assigned (p-value 
<0.001) (Fig. 2). When relating the changes in patients 
treated with ALA, GABA or the combination, and com-
paring them with changes in the group of patients who 
received placebo, we observed the existence of a large 
percentage of patients with negative changes within this 
group (Fig. 3). When observing the patients who re-
ceived ALA, we found that 9/20 (45%) of these patients 
did not presented changes, while the remaining 11/20 
(55%) had positive changes or full recovery in the case. 
Among the patients treated with GABA, 10/20 (50%) 
remained unchanged while the rest manifested decrease 
in the burning. Among those who were given the com-
bination of both drugs, only 6/20 (30%) remained un-
changed while 14/20 (70%) had positive changes. Final-
ly, and within the group of patients receiving placebo, 
51/60 (85%) remained unchanged or worsened while 
9/60 (15%) had positive changes. The calculation of odds 
ratios determined that the possibility of presenting posi-
tive changes (or total resolution of the case) for patients 
treated with ALA was 7 times higher than for those re-
ceiving placebo. For those patients who received GABA, 
that possibility was 5.7 times higher than for the control 
group and for the patients who received ALA and GABA 
together, that possibility was 13.2 times higher than for 
the control patients group (Table 1).
Fig. 1. Analysis of the changes after one month of treatment.
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Fig.  2. Analysis of the changes after two months of treatment.
Fig.  3. Comparison of the changes caused by the different drugs after two months.
Treatment Percentage of Favorable Cases # 
Possibility of 
Favorable Results * 
Alpha lipoic Acid  
(ALA) 55% 7 times better 
Gabapentin 
 (GABA) 50% 5.7 times better 
Combination 
(ALA+GABA) 70% 13.2 times better 
Table 1. Favorable changes after two months of treatment.
# Includes Patients with total case resolution.
* = ( p value<  0,001) compared with the placebo group.
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Discussion
 The communication of different therapeutic measures 
to control the BMS is wide in the world literature (11-
20). The Gabapentin was used by White et al. (15) in 
a case of a patient with BMS obtaining healing of the 
case and it was subsequently used by Heckmann et al. 
(16) who conducted a study with gabapentin in 15 pa-
tients, where the initial dose was 300 mg / day and then 
grew at a rate of 300 mg every 48 hours to a maximum 
of 2400 mg / day. Seven of the patients were treated 
for two weeks, 6 patients for four weeks and another 2 
patients for six weeks. Although 2 patients (13%) indi-
cated a decrease in pain of three points and another 2 
patients (13%) showed a decrease of two points on the 
VAS (visual analogue scale), the authors concluded that 
gabapentin has little or no effect on the treatment of 
BMS. In our study, we used GABA individually, with 
fixed doses of 300 mg daily for two months, getting no 
major differences with the published studies, although 
obtaining improvements when used it in combination 
with ALA. Femiano et al. (17) used the ALA at a dose 
of 600 mg / day and psychotherapy, in a parallel group 
and placebo-controlled trial. This drug was chosen for 
its neuroregenerative properties, demonstrated in the 
treatment of diabetic neuropathy, another disease with 
similar characteristics to the BMS that causes chronic 
pain. In the group treated with a total of 48 patients, 5 
patients (10%) experienced a slight improvement, 19 pa-
tients (40%) a clear improvement and 15 patients (31%) 
recovered from the BMS. The 81% of patients treated 
with the combination of ALA + Psychotherapy experi-
enced some improvement. In the placebo group only 6 
patients (13%) experienced improvement, and this one 
was classified as mild. At six months 19 patients (49%) 
who had experienced improvement after two months 
of treatment with ALA worsened. The same group has 
published other studies with ALA under different con-
ditions but with similar results. Lopez Jornet  et al. (20) 
also used ALA in 30 patients but at a concentration of 
800 mg daily for eight weeks with no statistically signif-
icant differences when comparing the treatment group 
with the control group. Carbone et al. (12) conducted 
a randomized, double-blind placebo-controlled study 
among 54 women and 12 men who used 400 mg of ALA 
daily together with vitamins, forming three groups ad-
ministered, for 16 weeks, with 400 mg / day of ALA, 
400 mg / day of ALA + vitamins and Placebo, getting 
similar effects in all three groups demonstrating a lack 
of efficacy of ALA in BMS, as this did not produce bet-
ter effects than placebo. In a review of a series of 31 
patients with BMS who took 600 mg / day in divided 
doses of ALA, Steele et al. (13) determine that the drug 
was beneficial in only 11 patients of all patients sur-
veyed. Cavalcanti and da Silveira (14) performed a ran-
domized double-blind, placebo-controlled trial between 
48 patients divided into two treatment cycles alternating 
20-day 200 mg / day of ALA and 100 mg / day of cellu-
lose starch, but were not able to demonstrate the greater 
efficacy of ALA over placebo. In our experience with 
the administration of ALA in 20 patients, with a daily 
dose of 600 mg for two months, we obtained similar 
results to those of Femiano et al. (17), with a decrease of 
the burning sensation in 55% of patients treated, being 
the possibility of favorable changes 7 times higher for 
patients who received ALA than for the control group. 
Note that in our study we also indicated as a treatment 
for one group the combination of ALA + GABA to try 
to produce an action on both peripheral and central no-
ciceptive system, obtaining with this combination the 
best results. Although effective treatments have been 
exposed to particular cases, we are still looking for a 
drug therapy that could be effective for most patients 
with BMS.
Conclusions
Gabapentin and Alpha Lipoic Acid used both individu-
ally and jointly, were beneficial for reducing the burn-
ing in patients with BMS. The most favorable results 
were obtained with the administration of both drugs. 
To establish specific therapies in the treatment of BMS, 
further study of the pathophysiological mechanisms in-
volved in its pathogenesis would be required, as well 
as determine the neurological changes involved in this 
disease, focusing on this entity within the Central Sen-
sitization Syndromes. Given the limitations in time and 
in the number of patients in our study, we recommend 
conducting multicenter clinical trials in more prolonged 
treatments, based on the combined use of drugs acting 
at different levels of the nociceptive system, since that 
could be the key to future advances in the treatment of 
this disease.
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